News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer
Breast Cancer
Jan 29, 2025, 22:27

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer

Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, shared on X:

“Phase 3 KEYNOTE756 trial –

1st interim analysis:

Pembro + chemo

pCR in high-risk early ER+/HER2− Breast Cancer (24.3% vs 15.6%)

Manageable safety

EFS data maturing. ”

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial | Nature Medicine

Authors: Fatima Cardoso, Joyce O’Shaughnessy, Zhenzhen Liu, Heather McArthur, Peter Schmid, Javier Cortes, Nadia Harbeck, Melinda L. Telli, David W. Cescon, Peter A. Fasching, Zhimin Shao, Delphine Loirat, Yeon Hee Park, Manuel Gonzalez Fernandez, Gábor Rubovszky, Laura Spring, Seock-Ah Im, Rina Hui, Toshimi Takano, Fabrice André, Hiroyuki Yasojima, Yu Ding, Liyi Jia, Vassiliki Karantza, Konstantinos Tryfonidis, Aditya Bardia

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer

Aditya Bardia cancer David W. Cescon Delphine Loirat Fabrice Andre Fatima Cardoso Gábor Rubovszky Heather McArthur Hiroyuki Yasojima Javier Cortés Joyce O'Shaughnessy Konstantinos Tryfonidis Kristina Jankovic Laura Spring Liyi Jia Manuel Gonzalez Fernandez Melinda L. Telli Nadia Harbeck OncoDaily Oncology Peter A. Fasching Peter Schmid Rina Hui Seock-Ah Im Toshimi Takano Vassiliki Karantza Yeon Hee Park Yu Ding Zhenzhen Liu Zhimin Shao
Special Coverage
Cancer Types
Apr 23, 2025, 13:57
Metastatic Lung Cancer: Causes, Symptoms, Treatment, and 2025 Advances in Therapy
Blog
Apr 23, 2025, 13:34
Kimryn Rathmell: I am thrilled to be joining to The Ohio State's James Cancer Hospital and Solove Research Institute as CEO
Blog
Apr 23, 2025, 13:23
Dr. Nita Radhakrishnan Wins Big at Precision Med India Awards 2025
Blog
Apr 23, 2025, 13:20
The Easter Discovery That Transformed Medicine: Marshall, Warren, and Helicobacter pylori
Blog
Apr 23, 2025, 13:17
Oliver Smithies: Scribbles That Changed the World of Genetics
Blog
Apr 23, 2025, 12:57
Darcy Burbage Honored with ONS’s 2025 Excellence in Social Media Impact Award
Blog
Apr 23, 2025, 11:43
Critical challenges in cell therapy development - Friends of Cancer Research
Blog
Apr 23, 2025, 11:31
When Circumstances Decide, Socioeconomic Status and Cancer Inequities in Europe - Youth Cancer Europe
Blog
Apr 23, 2025, 11:00
Olubukola Ayodele: The deep-rooted disparities ethnic minority groups face in breast cancer awareness, diagnosis in the UK
Science
Apr 23, 2025, 10:42
Federico Monaca: Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy
Insight
Apr 23, 2025, 10:35
Vignesh Packiam: I am generally aggressive in promoting bladder sparing for NMIBC
Blog
Apr 23, 2025, 10:33
Herbert Loong: It was a real pleasure meeting so many lung cancer friends